Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D, as the company faces down criticism of its recent efforts to develop and build its pipeline. He is ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Hosted on MSN2mon
Pfizer names oncology chief and company veteran Boshoff as chief scientific officerPfizer Inc. named oncology chief and company veteran Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been searching ...
Chris Boshoff, Pfizer’s chief oncology officer Its new chief oncology officer, Dr Chris Boshoff, said the focus will be on four main cancer types: breast cancer, genitourinary cancers including ...
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...
Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...
Response (Chris Boshoff): Data from ongoing studies will guide decisions, and Pfizer is focusing on high-value opportunities within its four R&D units. Geoff Meacham, Citibank: Inquired about ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results